Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
19.02 USD | -2.49% |
|
-4.71% | -66.01% |
12:05pm | Wolfe Research Downgrades 10x Genomics to Peer Perform From Outperform | MT |
25/06 | Guggenheim Downgrades 10x Genomics to Neutral From Buy | MT |
This article is reserved for members
Already a member?
Log InNot a member ?
Free registration![Consensus](/images/consensus_flch.gif)
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-66.01% | 2.33B | |
-9.89% | 11.57B | |
-12.79% | 7.37B | |
+28.65% | 5.44B | |
+0.41% | 5.31B | |
-17.87% | 3.74B | |
+7.41% | 2.58B | |
+28.84% | 2.23B | |
-11.30% | 2.21B | |
-14.32% | 1.67B |
- Stock Market
- Equities
- TXG Stock
- News 10x Genomics, Inc.
- UBS Adjusts 10x Genomics Price Target to $30 From $52, Maintains Neutral Rating